Healthcare Analysts discuss key considerations ahead of PTC Therapeutics’ top-line data from the Phase III APHENITY trial of PTC923 on an Analyst/Industry conference call to be held on April 28 at 10 am. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics price target raised to $51 from $48 at Credit Suisse
- PTC Therapeutics price target raised to $67 from $61 at Citi
- William Blair healthcare analysts to hold an analyst/industry conference call
- PTC Therapeutics reports Q1 EPS ($1.88), consensus ($1.39)
- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results